Source avec lien : Journal of Oncology Pharmacy Practice, 29(2). 10.1177/10781552221135121
Ce guide de pratique fondé sur des données probantes a été élaboré pour mettre à jour et traiter les nouvelles questions relatives à la manipulation des médicaments dangereux, notamment le respect des normes NAPRA (National Association of Pharmacy Regulatory Authorities) et USP 800 (United States Pharmacopeia), l’utilisation d’équipements de protection individuelle et le traitement dans divers contextes, y compris à domicile.
Background: This evidence-based practice guideline was developed to update and address new issues in the handling of hazardous drugs including being compliant with NAPRA (National Association of Pharmacy Regulatory Authorities) and USP 800 (United States Pharmacopeia) standards, the use of personal protective equipment and treatment in diverse settings including in the home setting. Methods: This guideline was developed from an adaptation and endorsement of existing guidelines and from three systematic reviews. Prior to publication, this guideline underwent a series of peer, patient, methodological and external reviews to gather feedback. All comments were addressed and the guideline was amended when required. This guideline applies to and is intended for all health care workers who may come into contact with hazardous drugs at any point in the medication circuit. Results: The recommendations represent a reasonable and practical set of procedures that the intended users of this guideline should implement to minimize the opportunity for accidental exposure. These recommendations are not limited to just the point of care, but cover the entire chain of handling of cytotoxics from the time they enter the institution until they leave in the patient or as waste. Conclusions: Decreasing the likelihood of accidental exposure to cytotoxic agents within the medication circuit is the main objective of this evidenced-based guideline. The recommendations differ slightly from previous guidelines due to new evidence.